Get the Stockscreener App
1.90
4.40%
0.08
Pre-market:
1.90
Alzamend Neuro Inc stock is traded at $1.90, with a volume of 29,957.
It is up +4.40% in the last 24 hours and down -7.32% over the past month.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
See More
Previous Close:
$1.82
Open:
$1.84
24h Volume:
29,957
Relative Volume:
0.29
Market Cap:
$7.22M
Revenue:
-
Net Income/Loss:
$-6.24M
P/E Ratio:
-0.3402
EPS:
-5.5853
Net Cash Flow:
$-8.09M
1W Performance:
-5.94%
1M Performance:
-7.32%
6M Performance:
-36.67%
1Y Performance:
-82.41%
1-Day Range:
$1.7804
$1.99
1-Week Range:
$1.69
$2.04
52-Week Range:
$1.69
$11.70
Alzamend Neuro Inc Stock (ALZN) Company Profile
Name
Alzamend Neuro Inc
Sector
Industry
Phone
844-722-6333
Address
3500 LENOX RD. NE, ATLANTA
Compare ALZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
1.90 | 6.92M | 0 | -6.24M | -8.09M | -5.5853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-21 | Initiated | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Stock (ALZN) Latest News
Momentum Shift: Will Alzamend Neuro Inc stock attract ESG investorsEarnings Performance Report & Stepwise Trade Signal Implementation - moha.gov.vn
Ascendiant Sticks to Their Buy Rating for Alzamend Neuro (ALZN) - The Globe and Mail
Ascendiant Capital Maintains Alzamend Neuro (ALZN) Buy Recommendation - Nasdaq
ALZN: Ascendiant Capital Lowers Price Target, Maintains Buy Rati - GuruFocus
Decliners Report: Why Alzamend Neuro Inc. stock is recommended by analystsQuarterly Market Review & Detailed Earnings Play Strategies - Улправда
Will Alzamend Neuro Inc. stock deliver long term returnsWeekly Profit Analysis & Consistent Profit Trade Alerts - Улправда
Is Alzamend Neuro Inc. stock attractive for ETFs2025 Support & Resistance & Community Verified Trade Signals - Улправда
Can Alzamend Neuro Inc. stock maintain growth trajectoryWeekly Trade Analysis & Risk Managed Trade Strategies - DonanımHaber
Why Alzamend Neuro Inc. stock is recommended by analystsQuarterly Growth Report & Verified Momentum Watchlists - Улправда
Can Alzamend Neuro Inc. stock sustain market leadershipJuly 2025 Chart Watch & Consistent Return Investment Signals - Улправда
Alzamend Neuro, Inc. SEC 10-Q Report - TradingView
Is Alzamend Neuro Inc stock attractive for passive investorsWeekly Investment Summary & Weekly Top Gainers Alerts - BỘ NỘI VỤ
Why Alzamend Neuro Inc. stock remains undervaluedJuly 2025 Analyst Calls & High Accuracy Trade Alerts - Newser
Alzamend Neuro (ALZN) Stock Analysis Report | Financials & Insights - Benzinga
Alzamend Neuro Mourns Loss of Director Andrew Woo - MSN
Is Alzamend Neuro Inc. stock attractive for passive investors2025 Earnings Impact & Daily Profit Focused Stock Screening - BỘ NỘI VỤ
Alzamend Neuro: Will Topline Data Spark Investor Interest? - RTTNews
Alzamend Neuro's AL001 formulation highlights its potential to treat disorders such a Alzheimer's - SelectScience
What margin trends mean for Alzamend Neuro Inc. stockWeekly Market Outlook & Verified Swing Trading Watchlists - newser.com
Why Alzamend Neuro Inc. stock could see breakout soonProduct Launch & High Return Trade Opportunity Guides - newser.com
Why Alzamend Neuro Inc. stock could benefit from AI revolutionTrade Risk Report & Daily Profit Maximizing Tips - newser.com
Can Alzamend Neuro Inc. stock sustain revenue growthMarket Risk Analysis & Pattern Based Trade Signal System - newser.com
Will Alzamend Neuro Inc. stock rally after Fed decisionsJuly 2025 Closing Moves & Safe Swing Trade Setup Alerts - newser.com
Will Alzamend Neuro Inc. stock reach all time highs in 2025Exit Point & Daily Technical Forecast Reports - newser.com
Alzamend completes clinical portion of phase II trial for lithium therapy - Investing.com Nigeria
Published on: 2025-11-19 13:20:00 - newser.com
Alzamend Neuro announces passing of board member Andrew H. Woo By Investing.com - Investing.com Australia
Comparing Alzamend Neuro Inc. in custom built stock radarsWeekly Risk Summary & Weekly Momentum Picks - newser.com
Alzamend Neuro announces completion of clinical portion of phase II clinical trial of AL001 "lithium in brain" study conducted at Massachusetts General Hospital - MarketScreener
Alzamend rises after completing mid-stage brain lithium study - TradingView
Alzamend Neuro (Nasdaq: ALZN) completes AL001 Phase II trial; 2026 lithium imaging data - Stock Titan
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants - Benzinga
Multi asset correlation models including Alzamend Neuro Inc.Oil Prices & Fast Exit/Entry Strategy Plans - newser.com
Is Alzamend Neuro Inc. stock cheap compared to fundamentalsWeekly Trend Summary & Safe Capital Growth Plans - newser.com
Alzamend Neuro Inc Stock (ALZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alzamend Neuro Inc Stock (ALZN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Horne William B. | Director |
Dec 19 '25 |
Sale |
2.12 |
3,333 |
7,059 |
0 |
| McGrath Lynne Fahey | Director |
Oct 23 '25 |
Sale |
2.29 |
30 |
69 |
25 |
| AULT MILTON C III | Director |
Oct 08 '25 |
Sale |
2.44 |
101,394 |
247,158 |
28,657 |
| AULT MILTON C III | Director |
Oct 09 '25 |
Sale |
2.32 |
20,397 |
47,390 |
8,260 |
| AULT MILTON C III | Director |
Oct 06 '25 |
Sale |
2.45 |
82,033 |
201,268 |
26,227 |
| AULT MILTON C III | Director |
Oct 07 '25 |
Sale |
2.49 |
57,379 |
142,954 |
68,848 |
| AULT MILTON C III | Director |
Oct 03 '25 |
Sale |
2.44 |
65,903 |
160,889 |
8,260 |
| AULT MILTON C III | Director |
Oct 01 '25 |
Sale |
2.35 |
36,777 |
86,378 |
94,849 |
| AULT MILTON C III | Director |
Oct 02 '25 |
Sale |
2.39 |
20,686 |
49,522 |
74,163 |
| AULT MILTON C III | Director |
Sep 29 '25 |
Sale |
2.31 |
38,324 |
88,490 |
35,192 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):